

Supplementary information

Tumor Necrosis Factor-Inducible Gene 6 Protein Ameliorates Chronic Liver Damage by Promoting Autophagy Formation in Mice

Supplementary Table 1. Sequences of primers used for qRT-PCR

Supplementary Figure 1. TSG-6 decreases inflammation in the liver of MCDE-treated mice.

qRT-PCR analysis of murine livers for $\text{tnf}\alpha$, $\text{Il-1}\beta$, cxcl1 and cxcl2 . Mean \pm SD results are plotted ($n \geq 4$ mice / group) (* $p < 0.05$)

Supplementary Figure 2. TSG-6 protects hepatocytes from PA-induced cell death by activating autophagy processes.

(a) Cell viability of AML12 cells treated with TSG-6 was analyzed using an MTS assay. After being exposed to palmitic acid (PA) (400 μM) for 24 hours, AML12 cells were treated with vehicle (PA), 3-MA (PA+3-MA) or TSG-6 with (PA+TSG-6+3-MA) or without 3-MA (PA+TSG-6) for 24 and 48 hours. As a control, AML12 cells were treated with equal volumes of vehicle without PA. The mean \pm SEM results obtained from three identical experiments are plotted. (b) Western blot assay and (c) cumulative densitometry analyses for LC3-II in these cell groups. GAPDH was used as an internal control. Data shown represent one of three experiments with similar results and the mean \pm SEM results obtained from three identical experiments are plotted (* $p < 0.05$ vs PA, # $p < 0.05$ vs PA+TSG-6 with 3-MA, & $p < 0.05$ vs PA+3-MA, \$ $p < 0.05$ vs control).

Supplementary Figure 3. TSG-6 is involved in activating CMA in ER stress-induced hepatocytes, increasing hepatocyte viability.

(a) qRT-PCR and (b) western blot assays of LAMP2A in the AML12 cells treated with either

27 scramble (scr) or *lamp2a* siRNA (si). GAPDH was used as an internal control. Immunoblots shown
28 represent one of three experiments with similar results. Mean±SD results obtained from three
29 identical experiments are plotted (*p<0.05 vs scr). (c) Either scr or *lamp2a* siRNA-transfected
30 AML12 cells were exposed to either tunicamycin (TM) (5 ng/ml) or palmitic acid (PA) (400 μM) for
31 24 hours, and then were treated with either vehicle or TSG-6 for 24 and 48 hours. Cell viability of
32 these cells was assessed using an MTS assay. The mean±SEM results obtained from three identical
33 experiments are plotted. (d) qRT-PCR analysis of *atg3*, *atg7*, *lc3*, and *lamp2a* expression in these cells
34 damaged by either TM (d) or (e) PA. Data represent the mean±SEM of three independent experiments
35 (\$p<0.05 vs Control (scr-transfected cells with vehicle), *p<0.05 vs TM or PA with scramble RNA,
36 #p<0.05 vs TM or PA+TSG-6 with *lamp2a* siRNA, &<0.05 vs TM or PA with *lamp2a* siRNA).

37

38 **Supplementary Figure 4. 3-MA, an autophagy inhibitor, rarely affects the healthy liver.**

39 (a) H&E-stained liver sections from representative normal mice with (normal+3-MA) or without 3-
40 MA (normal) treatment (X40). (b) The ratios of liver to body weight (LW/BW) of these mice. (c)
41 qRT-PCR analysis for *atg3*, *atg7* and *lc3* in livers from control mice treated with vehicle or 3-MA.
42 The results are displayed as the mean±SEM (n ≥ 3 mice / group). (d) Western blot analysis for LC3 in
43 these groups. GAPDH was used as an internal control. Data shown represent one of three experiments
44 with similar results.

45

46





47


48

S1 Table. Sequences of primers used for qRT-PCR

Mouse

Gene	Forward sequence	Reverse sequence
<i>atg3</i>	GAGGCTACCCTAGACACAAGG	GGGTGCCGTTGCTCATCATA
<i>atg7</i>	CTTCGCCCCCTTTAATAGTGC	TGAACTCCAACGTCAAGCGG
<i>lc3</i>	TTATAGAGCGATACAAGGGGGAG	CGCCGTCTGATTATCTTGATGAG
<i>lamp2a</i>	TTGTGGCAGGGTTGATGTTA	CACCCACTCCAACCTCCAACCT
<i>tnf-α</i>	TCGTAGCAAACCAACCAAGTG	ATATAGCAAATCGGCTGACG
<i>il-1β</i>	ACTCCTTAGTCCTCGGCCA	TGGTTTCTTGTGACCCTGAGC
<i>cxcl1</i>	CCCAAACCGAAGTCATAGCC	TCAGAAGCCAGCGTTCACC
<i>cxcl2</i>	GCCCAGACAGAAGTCATAGCC	TTCTCTTTGGTTCTTCCGTTGA
<i>9 s</i>	GACTCCGGAACAAACGTGAGG	CTTCATCTTGCCCTCGTCCA








\$: vs Control (no treatment)

* : vs PA + vehicle




: vs PA+TSG-6 +3-MA




& : vs PA+3-MA





□ No Treat ■ scr+TM or PA ■ scr+TSG-6+TM or PA ■ siRNA+TSG-6+TM or PA □ siRNA+TM or PA



a**b****c****d**